Abstract
Publisher Summary Plasma cell dyscrasias are defined as hematological disorders with monoclonal proliferation of the cells from later stages of B lymphocyte-lineage differentiation. Advances in molecular biology have made it possible to elucidate the mechanisms of proliferation and differentiation of plasma cells both from patients with plasma cell dyscrasias and from normal individuals. Especially in mice, plasmacytomagenesis is well defined through experiments with the hyperexpression of cytokines and oncogenes and with viral infection. The experimentally developed tumors in mice models are extremely useful for understanding the mechanisms of oncogenic transformation of human counterparts. Although the role of oncogenes in human multiple myeloma is not well understood, remarkable progress has been made in cytokine study. Interleukin-6 (IL-6) has been identified as a major growth factor for myeloma or plasmacytoma, and it is now clear that blockade of the IL-6 function can inhibit myeloma cell growth and improve the clinical status of patients. However, further studies is required to elucidate the intracellular events, such as signal transduction and gene regulation, in myeloma cells. An approach based on these findings should provide a new therapeutic strategy for myeloma.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
